









市场行情
/
股票
/
nasdaq-hrow
/

Harrow Inc

HROW

41.300USD

+0.280+0.68%

收盘 11/26, 16:00（美东）报价延迟15分钟

1.53B总市值

亏损市盈率 TTM



Harrow Inc

41.300

+0.280+0.68%

概览公司财务分析

概览

公司

财务

分析

关于 Harrow Inc 公司

Harrow, Inc. 是一家眼科药品公司。该公司致力于为美国市场发现、开发和销售眼科药品。它提供全面的处方药和非处方药产品组合。它拥有北美品牌眼科药品组合的商业权利，所有这些产品均以 Harrow 的名义销售。它拥有并经营 ImprimisRx，这是一家专注于眼科的药物配制企业。它拥有各种产品的美国商业权利：IHEEZO、VEVYE、TRIESENCE、VIGAMOX、ILEVRO、FLAREX、NATACYN、ZERVIATE 等。VIGAMOX（盐酸莫西沙星滴眼液）0.5%，是一种氟喹诺酮类抗生素滴眼液，用于治疗由敏感菌株引起的细菌性结膜炎。 IHEEZO（盐酸氯普鲁卡因眼用凝胶）3%是一种用于眼表麻醉的低粘度凝胶。

Harrow Inc简介



公司代码HROW

公司名称Harrow Inc

上市日期Feb 08, 2013

CEOMr. John P. Saharek

员工数量382

证券类型Ordinary Share

年结日Feb 08

公司地址1A Burton Hills Blvd

城市NASHVILLE

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编37215

电话16157334731

网址https://www.harrow.com/

公司代码HROW

上市日期Feb 08, 2013

CEOMr. John P. Saharek

Harrow Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.89M

+11.03%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

777.84K

+36.92%

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Perry J. Sternberg

Lead Independent Director

Mr. Randall E. Pollard, CPA

Chief Accounting Officer

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.89M

+11.03%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

777.84K

+36.92%

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Perry J. Sternberg

Lead Independent Director

收入明细

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Product Sales Net

63.66M

0.00%

Transfer of acquired product sales/profit

85.00K

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Product Sales Net

63.66M

0.00%

Transfer of acquired product sales/profit

85.00K

0.00%

股东统计

更新时间: 11月25日周二

持股股东

股东类型

持股股东

占比

Opaleye Management Inc.

10.54%

Baum (Mark L)

7.79%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.03%

Private Capital Management

5.01%

其他

65.61%

持股股东

占比

Opaleye Management Inc.

10.54%

Baum (Mark L)

7.79%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.03%

Private Capital Management

5.01%

其他

65.61%

股东类型

持股股东

占比

Investment Advisor

20.52%

Investment Advisor/Hedge Fund

19.69%

Individual Investor

15.70%

Hedge Fund

14.61%

Research Firm

2.10%

Pension Fund

0.83%

Bank and Trust

0.36%

Insurance Company

0.03%

Private Equity

0.02%

其他

26.13%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

360

21.75M

58.77%

-3.27M

2025Q2

345

26.63M

72.57%

-2.99M

2025Q1

354

25.78M

70.87%

-4.22M

2024Q4

350

26.13M

73.38%

-4.49M

2024Q3

325

25.90M

72.95%

-2.80M

2024Q2

296

24.70M

70.19%

-6.36M

2024Q1

284

26.34M

74.95%

-7.20M

2023Q4

279

28.26M

80.94%

-4.94M

2023Q3

275

28.51M

81.73%

-152.59K

2023Q2

265

25.64M

85.30%

+312.85K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Opaleye Management Inc.

3.90M

10.55%

-35.00K

-0.89%

Jun 30, 2025

Baum (Mark L)

2.89M

7.8%

+286.66K

+11.03%

Jul 21, 2025

BlackRock Institutional Trust Company, N.A.

2.25M

6.09%

-21.27K

-0.94%

Jun 30, 2025

The Vanguard Group, Inc.

1.86M

5.03%

+3.81K

+0.21%

Jun 30, 2025

Private Capital Management

1.95M

5.26%

+54.73K

+2.90%

Jun 30, 2025

Kaufman (Daniel)

1.68M

4.55%

-222.91K

-11.69%

Aug 12, 2024

State Street Investment Management (US)

773.11K

2.09%

-13.38K

-1.70%

Jun 30, 2025

Boll (Andrew R)

777.84K

2.1%

+209.75K

+36.92%

Apr 21, 2025

Geode Capital Management, L.L.C.

810.80K

2.19%

+36.72K

+4.74%

Jun 30, 2025

Royce Investment Partners

553.69K

1.5%

+226.60K

+69.28%

Jun 30, 2025

持股ETF



更新时间: 11月2日周日

机构名称

占比

SPDR S&P Pharmaceuticals ETF

2.45%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.84%

Invesco Dorsey Wright Healthcare Momentum ETF

0.94%

First Trust Small Cap Growth AlphaDEX Fund

0.79%

iShares U.S. Pharmaceuticals ETF

0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

0.47%

First Trust Small Cap Core Alphadex Fund

0.36%

iShares Micro-Cap ETF

0.32%

ProShares Ultra Nasdaq Biotechnology

0.18%

Invesco Nasdaq Biotechnology ETF

0.18%

SPDR S&P Pharmaceuticals ETF

占比2.45%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.84%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.94%

First Trust Small Cap Growth AlphaDEX Fund

占比0.79%

iShares U.S. Pharmaceuticals ETF

占比0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.47%

First Trust Small Cap Core Alphadex Fund

占比0.36%

iShares Micro-Cap ETF

占比0.32%

ProShares Ultra Nasdaq Biotechnology

占比0.18%

Invesco Nasdaq Biotechnology ETF

占比0.18%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Harrow Inc的前五大股东是谁？



Harrow Inc 的前五大股东如下：
Opaleye Management Inc.持有股份：3.90M，占总股份比例：10.55%。
Baum (Mark L)持有股份：2.89M，占总股份比例：7.80%。
BlackRock Institutional Trust Company, N.A.持有股份：2.25M，占总股份比例：6.09%。
The Vanguard Group, Inc.持有股份：1.86M，占总股份比例：5.03%。
Private Capital Management持有股份：1.95M，占总股份比例：5.26%。